A monthly injectable GLP-1 drug from Pfizer’s $10 billion Metsera acquisition is now on track for a Phase 3 program spanning 10 pivotal studies this year. While Pfizer’s pipeline spans internally developed and in-licensed assets for other targets, the pharma company says the Metsera drug is the foundation for its obesity strategy pursuing monotherapies and combination treatments.
The post Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity appeared first on MedCity News.
